Detalhe da pesquisa
1.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32469185
2.
Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping.
Future Oncol
; 19(10): 683-696, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-36999526
3.
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.
Future Oncol
; 18(9): 1039-1054, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-34918545
4.
Local treatment of stage IIIA-N2 nonsmall cell lung cancer: surgery and/or radiotherapy.
Curr Opin Oncol
; 32(1): 54-62, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31688138
5.
Mortality after lung transplantation: a single-centre cohort analysis.
Transpl Int
; 33(2): 130-141, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31612514
6.
Cancer in the time of COVID-19: expert opinion on how to adapt current practice.
Eur Respir J
; 55(5)2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32299866
7.
Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma.
Front Immunol
; 14: 1148798, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37026006
8.
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 9(9): 1260-1266, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37270698
9.
Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.
Biomedicines
; 10(3)2022 Mar 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35327475
10.
New Implications of Patients' Sex in Today's Lung Cancer Management.
Cancers (Basel)
; 14(14)2022 Jul 13.
Artigo
Inglês
| MEDLINE | ID: mdl-35884463
11.
External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma.
Cancers (Basel)
; 14(13)2022 Jun 29.
Artigo
Inglês
| MEDLINE | ID: mdl-35804954
12.
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Clin Cancer Res
; 28(6): 1117-1126, 2022 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34789481
13.
Recent developments in the treatment of small cell lung cancer.
Eur Respir Rev
; 30(161)2021 Sep 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34261744
14.
DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis.
J Thorac Oncol
; 16(9): 1461-1478, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34082107
15.
Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle.
Cancers (Basel)
; 13(7)2021 Apr 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33918147
16.
Nivolumab and anti-HCV activity, a case report.
Acta Clin Belg
; 76(5): 392-396, 2021 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-32182200
17.
Caspr2 autoantibody-associated Morvan syndrome predating thymoma relapse by 30 months.
Lung Cancer
; 153: 117-119, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33485137
18.
A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient: New osteoblastic bone lesions in a lung cancer patient may represent bone flare and should not be misdiagnosed as disease progression.
J Belg Soc Radiol
; 104(1): 18, 2020 Apr 27.
Artigo
Inglês
| MEDLINE | ID: mdl-32377620
19.
Correction: A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient.
J Belg Soc Radiol
; 104(1): 28, 2020 Jun 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32566892
20.
Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients.
Cancers (Basel)
; 12(4)2020 Apr 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32252405